This Algorithm provides high level steps for prescribing and dispensing of Thalidomide BMS®.

The FAQs (Frequently Asked Questions) section in the Thalidomide BMS Healthcare Professional Information Pack provides answers to common questions that healthcare professionals may have about the medication.

This pack contains the all the additional Risk Minimisation Materials required to prescribe and dispense Thalidomide BMS®. It also contains important reporting forms, information for patients, prescribing tools, and the Pharmacy Registration Form. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing Thalidomide BMS® for any patient.

This brochure contains the information needed for prescribing and dispensing of Thalidomide BMS®, including information about the Pregnancy Prevention Programme. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing Thalidomide BMS® for any patient. Please also refer to the Summary of Product Characteristics (SmPC) for Thalidomide BMS®.

This brochure should be given to patients receiving treatment with Thalidomide BMS®, as it provides important information about the Thalidomide BMS® Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking Thalidomide BMS® and how to report side effects.

This Risk Awareness Form must be completed for each male patient prior to the initiation of their Thalidomide BMS® treatment. It is mandatory that male patients receive counselling and education to be made aware of the risks of Thalidomide BMS®. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of Thalidomide BMS®.

This card should be given to all patient as it reminds patients of the key educational information and risks of treatment with Thalidomide BMS®.

This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense Thalidomide BMS®. In order to ensure that the actions to minimise the risk of foetal exposure are carried out for all patients, dispensing of Thalidomide BMS® will only be allowed from pharmacies registered with BMS.

A newly completed Prescription Authorisation Form must accompany each Thalidomide BMS® prescription to confirm that the patient has been counselled about the teratogenic risk of Thalidomide BMS® and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.

This Risk Awareness Form must be completed for each woman of childbearing potential prior to the initiation of their Thalidomide BMS® treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of Thalidomide BMS®. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of Thalidomide BMS®.

This Risk Awareness Form must be completed for each woman of non-childbearing potential prior to the initiation of their Thalidomide BMS® treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of Thalidomide BMS®. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of Thalidomide BMS®.